Aurobindo Pharma Research Report By Sharekhan

Acquisition of Natrol to expand horizon: Having strengthened its positioning in generic injectables, controlled substances and other niche prescriptions and institutional business, Aurobindo Pharma (Aurobindo) is set to expand its presence in nutraceutical and health supplement markets through the acquisition of Natrol LLC. The company emerged as the highest bidder at a consideration of $132.5 million for Natrol, which was seeking bankruptcy in a US court. Natrol has seven key brands, an extensive distribution network in the USA, Europe and some other Asian countries, an e-commerce platform and manufacturing assets in California (USA). The acquisition will provide a readymade launchpad for Aurobindo to play in the fast growing nutraceutical and health supplement markets (market size estimated to be $30 billion in USA). Natrol is currently a profitable company (thus earning accretive for the company from day one) and has immense potential to grow.

Download Aurobindo Pharma Sharekhan Report